Hyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option

SOUTH SAN FRANCISCO, Calif., March 13, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today the completion of its follow-on offering of 2,875,000 shares of common stock. In addition, the underwriters exercised their over-allotment option in full and purchased an additional 431,250 shares of common stock. All such shares were sold by Hyperion at the follow-on offering price of $20.75 per share. The net proceeds to Hyperion from this offering are approximately $64.5 million, after deducting underwriter discounts and commissions. Leerink Swann LLC and Cowen and Company, LLC acted as joint book-running managers for the offering, and Needham & Company, LLC and JMP Securities LLC acted as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 7, 2013. This offering is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814, and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by calling (631) 274-2806, or faxing (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology.

CONTACT: Shari Annes, Investor Relations (650) 888-0902 sannes@annesassociates.com Kristie Kuhl, Media Relations (203) 556-7417 kkuhl@makovsky.comSource:Hyperion Therapeutics, Inc.